Christopher Durant Turner - 05 Jan 2026 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Reporting relationship: Chief Medical Officer
Issuer ticker: NUVL
Reported as of: 05 Jan 2026
Net transaction value: -$721,320
SEC form: 4
Accepted by SEC: 07 Jan 2026, 17:26:13 UTC
Prior SEC filing: 08 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Nathan McConarty, attorney-in-fact

Key filing fact

Christopher Durant Turner filed Form 4 for Nuvalent, Inc. (NUVL) on 07 Jan 2026.

Key facts

This page summarizes Christopher Durant Turner's Form 4 filing for Nuvalent, Inc. (NUVL).
9 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Jan 2026, 17:26.

Change

Previous filing in this sequence was filed on 08 Jan 2025.
Current net transaction value: -$721,320.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001862146 Primary reporting owner

Turner Christopher Durant

Relationship: Chief Medical Officer
Address: C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Signature: /s/ Nathan McConarty, attorney-in-fact
Signature date: 07 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVL transaction

Class A Common Stock

Sale

Transaction value: $83,668
Shares: -871
Change %: -1.4%
Price: $96.06
Shares after: 61,676
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F1, F2

NUVL transaction

Class A Common Stock

Sale

Transaction value: $108,375
Shares: -1,119
Change %: -1.8%
Price: $96.85
Shares after: 60,557
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F1, F3

NUVL transaction

Class A Common Stock

Sale

Transaction value: $188,965
Shares: -1,929
Change %: -3.2%
Price: $97.96
Shares after: 58,628
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F1, F4

NUVL transaction

Class A Common Stock

Sale

Transaction value: $31,231
Shares: -317
Change %: -0.54%
Price: $98.52
Shares after: 58,311
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F1, F5

NUVL transaction

Class A Common Stock

Sale

Transaction value: $127,807
Shares: -1,321
Change %: -2.3%
Price: $96.75
Shares after: 56,990
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1, F6

NUVL transaction

Class A Common Stock

Sale

Transaction value: $159,135
Shares: -1,635
Change %: -2.9%
Price: $97.33
Shares after: 55,355
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1, F7

NUVL transaction

Class A Common Stock

Sale

Transaction value: $22,140
Shares: -225
Change %: -0.41%
Price: $98.40
Shares after: 55,130
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1, F8

NUVL transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +17,500
Change %: +32%
Price: $0.000000
Shares after: 72,630
Date: 07 Jan 2026
Ownership: Direct
Footnotes: F9

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 17,500
Exercise price: $106.82
Footnotes: F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 10 footnotes

Footnote F1

The sale was effected pursuant to a durable Rule 10b5-1 sell-to-cover instruction letter entered into on December 6, 2023 to satisfy the reporting person's tax withholding obligations upon the vesting of previously granted equity awards.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.34 to $96.33, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) of this Form 4.

Footnote F3

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.34 to $97.33, inclusive.

Footnote F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.34 to $98.33, inclusive.

Footnote F5

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.34 to $99.10, inclusive.

Footnote F6

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.03 to $97.02, inclusive.

Footnote F7

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.03 to $98.02, inclusive.

Footnote F8

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.04 to $98.74, inclusive.

Footnote F9

Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following January 7, 2026, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

Footnote F10

The shares underlying this option vest over the four years following January 7, 2026 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.